stockrow
Saturday 7 November 2026
Export ONCO’s income statement to Excel — free account
Onconetix, Inc.
ONCO Healthcare Biotechnology
Onconetix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $815,400.00, down 67.7% from fiscal 2024.
- Revenue
- −83.9%
- EPS
- +99.5%
- Free cash flow
- −36.0%
Quarter to June 2026, against a year earlier
6.81
6.26
+1,138.18%
Follow ONCO
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | — | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — |
Altman Z-Score |
(9.75) | (12.96) | (2.40) | — | — | — | — | — |
P/S ratio |
2.99 | 2.14 | 0.00 | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(20.98) | (30.43) | (5.72) | — | — | — | — | — |
Beneish M-Score |
33.30 | 0.76 | — | — | — | — | — | — |
P/Operating CF |
(0.79) | (5.88) | (0.87) | — | — | — | — | — |
P/B ratio |
0.15 | 0.63 | 2.66 | — | — | — | — | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | — | — | — | — | — |
EV/Sales |
(3.27) | 1.93 | 0.00 | — | — | — | — | — |
EV/EBITDA |
0.15 | 0.00 | 0.02 | — | — | — | — | — |
EV/Operating CF |
0.28 | (0.46) | 0.05 | — | — | — | — | — |
EV/FCF |
0.27 | (0.46) | 0.04 | — | — | — | — | — |
Quick Ratio |
0.61 | 0.04 | 0.27 | 6.57 | 1.27 | 63.37 | 79.94 | — |
Current Ratio |
0.66 | 0.05 | 0.34 | 6.69 | 1.88 | 66.91 | 79.94 | — |
Net Debt/EBITDA |
0.29 | 0.01 | 0.13 | 1.91 | 0.57 | 2.66 | 6.88 | — |
Debt/Assets |
0.00% | 0.00% | 0.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.03 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.62 | 0.18 | 0.36 | 0.64 | 0.51 | 0.80 | 0.75 | — |
Capex/Depreciation |
0.00 | 0.00 | (8.58) | (1.37) | (0.39) | (3.81) | 0.00 | — |
Interest Coverage |
(23.78) | (40.13) | (53.65) | — | — | (71.77) | (30.20) | — |
| (127.79%) | (1,184.21%) | (314.47%) | (113.42%) | (130.89%) | (40.24%) | (20.53%) | — | |
| (58.49%) | (101.81%) | (65.73%) | (91.96%) | (102.44%) | (39.65%) | (36.24%) | — | |
ROIC |
(105.85%) | (447.13%) | 0.00% | 0.00% | 0.00% | (238.54%) | 0.00% | — |
Return on Tangible Assets |
512.23% | 340.90% | 331.31% | (60.48%) | (279.60%) | (47.53%) | (18.40%) | — |
Average Days of Receivables |
155.28 | 3.72 | 934.03 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
(8.11%) | 6.12% | 3,332.31% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
863.86% | 444.99% | 25,249.06% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.74 | 0.96 | 0.93 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
9.11% | 17.38% | 563.76% | 0.00% | 0.00% | 0.00% | — | — |
Graham Net Nets |
(1.27) | (3.46) | (21.52) | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | — | — | — | — | — |
Earnings Yield |
(3,386.83%) | (8,289.50%) | (1,069.94%) | — | — | — | — | — |
Free Cash Flow Yield |
(397.88%) | (194.90%) | (528.42%) | — | — | — | — | — |
Revenue per Share |
43.37 | 4,206.83 | 581.16 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(514.81) | (17,493.00) | (134,919.53) | (120,184.25) | (108,598.29) | (91,911.71) | (12,695.45) | — |
Capex per Share |
0.00 | (47.50) | (60,945.76) | (128.84) | (100.94) | (626.88) | 0.00 | — |
Free Cash Flow per Share |
(514.81) | (17,540.50) | (195,865.29) | (120,313.08) | (108,699.23) | (92,538.58) | (12,695.45) | — |
Cash per Share |
277.70 | 1,077.50 | 45,244.39 | 356,759.71 | 102,451.72 | 228,905.36 | 93,100.98 | — |
Shareholders Equity per Share |
838.54 | 14,237.67 | 13,952.91 | 310,147.54 | 76,850.75 | 251,483.52 | 92,294.72 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
838.54 | 14,237.67 | 13,952.91 | 310,147.54 | 76,850.75 | 251,483.52 | 92,294.72 | — |
Free Cash Flow |
(9.68) | (10.52) | (19.72) | (8.68) | (2.05) | (1.74) | (0.83) | — |
Working Capital |
(3.07) | (17.34) | (11.35) | 22.34 | 1.44 | 4.53 | 5.98 | — |
Capital Expenditures |
— | (0.03) | (6.13) | (0.01) | 0.00 | (0.01) | 0.00 | — |
Net Current Asset Value |
(3.10) | (18.69) | (80.28) | 22.34 | 1.44 | 4.52 | 5.98 | — |
EV/EBIT |
0.15 | 0.00 | 0.02 | — | — | — | — | — |
Capex to Sales |
0.00 | 0.01 | 104.87 | 0.00 | 0.00 | 0.00 | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
3.75 | 193.23 | 11.78 | 0.48 | 0.43 | 0.20 | 0.09 | — |
Cash ROIC |
(46.12%) | (114.53%) | (324.40%) | (18.04%) | (60.62%) | (19.26%) | (6.85%) | — |
Accounts Receivable Turnover |
4.38 | 28.78 | 0.63 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.07 | 0.32 | 0.35 | 0.01 | 0.02 | 0.07 | 0.01 | — |
Inventory Turnover |
1.70 | 6.86 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
3,515.40 | 941.10 | 1,630.15 | 80,477.13 | 43,397.76 | 8,088.87 | 11,193.33 | — |
Days of Inventory on Hand |
300.00 | 15.93 | 112.09 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
0.19 | 0.09 | 0.09 | 0.09 | 0.10 | 0.03 | 0.01 | — |
Average Payables |
2.77 | 4.54 | 3.40 | 1.04 | 0.33 | 0.04 | 0.04 | — |
Average Inventory |
0.11 | 0.21 | — | — | — | — | — | — |
Average Assets |
26.55 | 57.85 | 56.91 | 14.70 | 3.95 | 5.45 | 3.04 | — |
Average Common Equity |
12.15 | 4.97 | 11.90 | 11.92 | 3.09 | 5.37 | 5.37 | — |
Columns are period end dates · fundamentals updated 26 Oct 2026